Welcome to our dedicated page for Lite Strategy SEC filings (Ticker: LITS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lite Strategy, Inc. filings document the company’s public-company transition, operating results, Litecoin treasury strategy, and capital-allocation actions. Form 8-K disclosures include furnished financial results, the board-authorized common stock repurchase program, and equity securities activity tied to pre-funded warrants issued in a private placement.
The filings also cover governance and compensation matters, including annual meeting voting results, director elections and resignation, executive appointment to chief executive officer and the board, stock option grants, and approval of the 2026 Omnibus Equity Compensation Plan. SEC reports identify MEI Pharma, Inc. as the company’s former name and support the current Lite Strategy identity.
Lite Strategy, Inc. reported results of its fiscal 2026 Annual Meeting held on February 12, 2026. Stockholders approved the 2026 Omnibus Equity Compensation Plan, which became effective upon approval and supports the company’s future stock-based incentive awards.
Approval of the 2026 plan also satisfied the contingency for previously disclosed Replacement Options granted to Mr. Justin J. File to purchase 455,000 shares of common stock. Stockholders elected Mr. File and Mr. Joshua Riezman as directors to terms running through fiscal 2029, approved an advisory vote on executive compensation, and ratified CBIZ CPAs as independent auditors for the fiscal year ending June 30, 2026.
At the meeting, 19,437,130 shares of common stock were represented by proxy out of 36,785,397 shares outstanding and entitled to vote, indicating substantial shareholder participation.
Lite Strategy, Inc. (LITS) reported an amended insider transaction showing the grant of 180,000 stock options to its CEO, CFO and Secretary, who also serves as a director. The options have an exercise price of $2.02 per share and were granted on 11/14/2025.
These options were received as employment compensation and vest in 36 monthly installments, with the first installment vesting one month after the grant date, subject to continued service. The amendment states that a prior filing on 11/18/2025 inadvertently reported the number of options granted, and this filing corrects that amount to 180,000 options.
Lite Strategy, Inc. filed an amended report to correct the previously disclosed size of stock options granted to its Chief Executive Officer, Justin J. File. The original filing stated that Mr. File received options to purchase 635,000 shares of common stock, but the actual grant on November 14, 2025 was for options on 180,000 shares under the company’s existing equity plan.
To address this discrepancy, on November 20, 2025 the board approved additional “Replacement Options” for Mr. File to purchase 455,000 shares of common stock. These replacement options carry an exercise price of $2.02 per share and follow the same vesting terms as the original 180,000-share grant. The replacement options will only be issued if stockholders approve a new omnibus equity plan at the company’s 2026 annual meeting; they will be cancelled if that plan is not approved.
Lite Strategy, Inc. (LITS) reported an insider stock purchase by a company director. On 11/19/2025, the director bought 12,100 shares of Lite Strategy common stock in an open-market transaction coded "P" for purchase. The weighted-average purchase price was $1.8824 per share, with individual trades executed between $1.87 and $1.90 per share.
Following this transaction, the director beneficially owns 30,000 shares of Lite Strategy common stock in direct ownership. The filing notes that detailed trade-by-trade pricing information within the stated range is available upon request from the company, its security holders, or the SEC staff.
Lite Strategy, Inc. (LITS) reported a Form 4 showing that director Nicholas Glover received a customary annual grant of stock options. On 11/14/2025, he was granted options to purchase 55,000 shares of Lite Strategy common stock at an exercise price of $2.02 per share, expiring on 11/14/2035. These options are held as direct ownership.
The options vest over time as board compensation. 16.66666% of the grant vested on the grant date, with the remaining options vesting in equal monthly installments beginning 12/14/2025 and continuing on the first day of each month through 11/14/2026. The filing states the grant was received as compensation for service on the company’s Board of Directors.
Lite Strategy, Inc. (LITS) reported an equity award to one of its directors in the form of stock options. On 11/14/2025, the director received an option grant covering 55,000 shares of common stock at an exercise price of $2.02 per share. These options are a customary annual grant to non-employee directors and were received as compensation for board service. The options vest over time, with 16.66666% vesting on the grant date and the remaining portion vesting in equal monthly amounts beginning 12/14/2025 and continuing through 11/14/2026, encouraging ongoing alignment between the director’s interests and those of shareholders.
Lite Strategy, Inc. (LITS) reported that a non-employee director received stock option awards. On November 14, 2025, the director was granted a stock option to purchase 55,000 shares of common stock at an exercise price of $2.02 per share, exercisable through November 14, 2035. This grant is described as a customary annual award to non-employee directors and vests 16.66666% on the grant date, with the remainder vesting monthly from December 14, 2025 through November 14, 2026.
On the same date, the director also received a separate stock option for 10,000 shares of common stock at an exercise price of $2.02 per share, also expiring on November 14, 2035. This option is described as a customary grant upon appointment to the Board, as revised on November 14, 2025, and vests in 36 equal monthly installments beginning one month after the grant date, subject to continued service.
Lite Strategy, Inc. (LITS) reported that a non-employee director received a customary annual stock option grant. On 11/14/2025, the director was awarded options to purchase 55,000 shares of common stock at an exercise price of $2.02 per share as compensation for board service. The options vest over one year, with 16.66666% vesting on the grant date and the remaining options vesting in equal monthly amounts beginning 12/14/2025 and continuing through 11/14/2026. The options expire on 11/14/2035 and are held directly by the reporting person.
Lite Strategy, Inc. reported an insider equity award for its chief executive. A Form 4 shows that the CEO, CFO, Secretary and director received a stock option to buy 635,000 shares of common stock at an exercise price of $2.02 per share on 11/14/2025 as employment compensation. The option is scheduled to vest in 36 equal monthly installments, with the first installment vesting one month after the grant date, subject to continued service through each vesting date.